Navigation Links
Healthcare Realty Trust Announces Third Quarter Results
Date:11/10/2008

n

and amortization 13,456 12,664 39,878 39,734

Total adjustments 12,710 9,077 30,780 (1,725)

Funds From Operations -

Basic and Diluted $18,237 $14,563 $56,873 $53,749

Funds From Operations

Per Common Share - Basic $0.37 $0.31 $1.15 $1.15

Funds From Operations

Per Common Share - Diluted $0.36 $0.31 $1.13 $1.13

Weighted Average Common

Shares Outstanding -

Basic 49,530,813 46,683,619 49,438,796 46,680,455

Weighted Average Common

Shares Outstanding -

Diluted 50,614,173 47,601,330 50,481,469 47,596,154

RECONCILIATION OF FUNDS AVAILABLE FOR DISTRIBUTION (2):

(Dollars in thousands, except per share data)

(Unaudited)

Three Months Ended

September 30, 2008

Net Income $5,527

Gain on sales of real estate properties (746)

Total non-cash items included in cash

flows from operating activities (3) 17,310

Funds Available For Distribution $22,091

Funds Available For Distribution Per Common Share - Diluted 0.44

Weighted Average Common Shares Outstanding - Diluted 50,614,173

(1) Funds from operations ("FFO") is calculated according to the

definition of the National Association of Real Estate Investment

Trusts ("NAREIT") and is comprised primarily of net income and

depreciation from real estate, but is not adjusted for certain

non-cash income and expense items. Gains on the sale of real estate


'/>"/>

SOURCE Healthcare Realty Trust Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. World Publics See Government as Responsible for Ensuring Basic Healthcare, Food, and Education Needs
2. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
3. Wyeth to Present at the Credit Suisse Healthcare Conference
4. Velocity Emerges as Healthcare Technology Leader
5. Ford Motor Co. Tops First-Ever Healthcare Purchasing Power Survey
6. Quest Diagnostics to Speak at the 2008 Credit Suisse Healthcare Conference
7. Axway and Edifecs Form Strategic Partnership to Benefit Healthcare Payors
8. Live Event and Webcast: Blue Cross and Blue Shield Association Spearheads Major Initiative to Improve Healthcare Quality, Increase Cost Efficiency
9. Zimmer Holdings to Present at Credit Suisse 2008 Healthcare Conference
10. Chief Executive Officer Leaving Integrated Healthcare Holdings, Inc.
11. Allied Healthcare Net Income Increases
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 2Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 3Health News:Mouse mammary tumor virus can replicate in human cells 2Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:PRI Criticizes Guttmacher Report 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2